Biogen Idec Shifts Gears On Tysabri Relaunch
This article was originally published in The Pink Sheet Daily
Executive Summary
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.
You may also be interested in...
Biogen/Elan’s Tysabri Gets Positive NICE Recommendation
Natalizumab becomes first multiple sclerosis therapy recommended by NICE in the UK.
Biogen/Elan’s Tysabri Gets Positive NICE Recommendation
Natalizumab becomes first multiple sclerosis therapy recommended by NICE in the UK.
Tysabri Crohn’s sBLA Will Get Joint Advisory Committee Review
One of three progressive multifocal leukoencephalopathy deaths in Tysabri clinical database was in a Crohn’s patient.